Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Ticker SymbolPHAR
Company namePharming Group NV
IPO dateJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
AddressDarwinweg 24
CityLEIDEN
Stock exchangeLondon Stock Exchange
CountryNetherlands
Postal code2333 CR
Phone31715247400
Websitehttps://www.pharming.com/
Ticker SymbolPHAR
IPO dateJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data